Gway.Cd
GWAY.CD operates in the healthcare sector, specifically in the pharmaceuticals industry, and generates revenue primarily through the development and distribution of pharmaceutical products.
Business. GWAY.CD operates in the healthcare sector, specifically in the pharmaceuticals industry, and generates revenue primarily through the development and distribution of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
GWAY.CD operates in the healthcare sector, specifically in the pharmaceuticals industry, and generates revenue primarily through the development and distribution of pharmaceutical products.
GWAY.CD's capital structure is characterized by a debt-to-equity ratio of 1.57, indicating a relatively high level of leverage. The company's liquidity position is assessed as medium, with a current ratio of 0.49, suggesting that it may struggle to meet short-term obligations with its current assets. The company's free cash flow is negative at -320,350 CAD, and its operating cash flow is 1,806,460 CAD, indicating that while the company generates some cash from operations, it is not sufficient to cover capital expenditures.
In terms of profitability, GWAY.CD reported a net loss of 2,057,450 CAD and an operating loss of 958,940 CAD, with a return on equity of -20.47% and a return on assets of -6.38%. These figures are below the industry median for profitability metrics, indicating that the company is underperforming relative to its peers in the pharmaceuticals industry.
The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risk if market conditions in its primary market deteriorate.
Looking at the company's growth trajectory, there is no specific outlook provided for the current or next fiscal year. However, the company's operating income and net income are both negative, suggesting a challenging growth environment. The company's capital expenditures of -194,370 CAD indicate that it is investing in its operations, but the negative free cash flow suggests that these investments are not yet generating positive returns.
The risk assessment for GWAY.CD indicates a medium liquidity risk and a low dilution risk. The company's net cash is negative after subtracting total debt, which could impact its ability to fund operations without additional financing. The dilution risk is assessed as low, suggesting that the company is not expected to issue a significant number of new shares in the near term.
Recent events related to GWAY.CD include the filing of its latest financial statements, which show a continued net loss and negative operating income. There are no recent transcripts or other filings that provide additional insight into the company's operations or strategic direction.
- GWAY.CD is experiencing a net loss and negative operating income, indicating financial distress.
- The company's debt-to-equity ratio is high, suggesting a significant reliance on debt financing.
- The company's liquidity position is weak, with a current ratio below 1.
- There is no geographic or segment diversification disclosed, increasing exposure to market-specific risks.
- The company's capital expenditures are not generating positive free cash flow, indicating inefficiency in capital use.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- GWAY.CD Market data — financials · 2026-05-28